BCAT vs QCRH

The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 1/9, indicating weak fundamental strength. Despite a current price of $14.67 and a seemingly low P/E of 9.72, the complete lack of profitability across all margin metrics, an unsustainable 226.7% dividend payout ratio, and missing key financial data raise serious red flags. The stock's technical trend is deeply bearish, and insider sentiment is weak, further undermining confidence. While the 21.33% dividend yield appears attractive, it is not supported by earnings or cash flow, making it highly vulnerable to cuts.

QCRH exhibits a stable financial profile with a Piotroski F-Score of 4/9 and is currently undervalued, trading at $92.77, well below its Graham Number of $105.98 and Intrinsic Value of $220.96. The company demonstrates exceptional operational consistency, having beaten earnings estimates in nearly every quarter over the last 25 reporting periods. While technical trends and insider sentiment are currently bearish, the strong YoY revenue (17.10%) and earnings growth (19.40%) provide a powerful fundamental cushion. The valuation suggests a significant margin of safety for long-term investors.